FDA Approves Blue Earth Diagnostics’ Axumin Injection

Blue Earth Diagnostics has scored FDA approval for its Axumin diagnostic injection — or fluciclovine F18 — for the detection of recurrent prostate cancer, the company announced Tuesday.

The radioactive diagnostic agent was approved for use in positron emission tomography imaging in men with elevated blood levels of prostate specific antigen following treatment.

Axumin is the first product commercialized by Blue Earth Diagnostics, according to the company. — Anisa Jibrell